DrugPatentWatch Database Preview

Tapentadol hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for tapentadol hydrochloride and what is the scope of tapentadol hydrochloride patent protection?

Tapentadol hydrochloride is the generic ingredient in two branded drugs marketed by Depomed Inc and is included in three NDAs. There are seven patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tapentadol hydrochloride has two hundred and fifty-five patent family members in thirty-seven countries.

There are five drug master file entries for tapentadol hydrochloride. Six suppliers are listed for this compound.

Summary for tapentadol hydrochloride

International Patents:	255
US Patents:	7
Tradenames:	2
Applicants:	1
NDAs:	3
Drug Master File Entries:	5
Suppliers / Packagers:	6
Bulk Api Vendors:	32
Clinical Trials:	63
Patent Applications:	249
Formulation / Manufacturing:	see details
Drug Prices:	see low prices
DailyMed Link:	tapentadol hydrochloride at DailyMed

Pharmacology for tapentadol hydrochloride

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

Synonyms for tapentadol hydrochloride

(-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

175591-09-0

3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl) phenol hydrochloride

3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-phenol hydrochloride

3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol hydrochloride

3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol hydrochloride

3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol hdrochloride

3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol Hydrochloride

3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride

591T238

71204KII53

AB1008539

AK-43468

AX8210956

CHEMBL1201777

CS-0879

D10199

EBD2202137

FT-0674809

HY-70042A

JNS-024 ER

KB-80810

KS-00000OJT

MFCD00944992

Nucynta (TN)

Nucynta ER

Palexia retard

Palexia SR

Phenol, 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-, hydrochloride

R-331333

SCHEMBL238138

ST24049325

Tapentadol (hydrochloride)

Tapentadol HCl

Tapentadol HCl (1.0 mg/mL in Methanol)

Tapentadol hydrochloride (JAN)

Tapentadol hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material

Tydol|||Zyntap|||3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol hydrochloride

UNII-71204KII53

W-5241

X4992

ZELFLGGRLLOERW-YECZQDJWSA-N

US Patents and Regulatory Information for tapentadol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Depomed Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011		RX	Yes	No
Depomed Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011		RX	Yes	No			Y
Depomed Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-005	Aug 25, 2011		RX	Yes	Yes			Y	Y
Depomed Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-003	Aug 25, 2011		RX	Yes	No			Y

Expired US Patents for tapentadol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Depomed Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-001	Nov 20, 2008
Depomed Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011
Depomed Inc	NUCYNTA	tapentadol hydrochloride	SOLUTION;ORAL	203794-001	Oct 15, 2012
Depomed Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-002	Nov 20, 2008

Non-Orange Book US Patents for tapentadol hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,114,384	Process for the production of an abuse-proofed solid dosage form
8,192,722	Abuse-proof dosage form
8,323,889	Process for the production of an abuse-proofed solid dosage form
6,248,737	1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects

International Patents for tapentadol hydrochloride

Country	Document Number	Estimated Expiration
Mexico	2007009393
Hungary	E032099
Japan	6081337
Peru	03722006

Supplementary Protection Certificates for tapentadol hydrochloride

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0693475/01	Switzerland		PRODUCT NAME: TAPENTADOL; REGISTRATION NO/DATE: SWISSMEDIC 60530 20110222
2010 00036	Denmark
C0016	France		PRODUCT NAME: TAPENTADOL SOUS FORME DE SA BASE LIBRE OU SOUS FORME D'UN DE SES SELS D'ACIDES ACCEPTABLES DU POINT DE VUE PHYSIOLOGIQUE; NAT. REGISTRATION NO/DATE: NL40884 20111003; FIRST REGISTRATION: DE - 76261.00.00 20100819
C/GB11/031	United Kingdom		PRODUCT NAME: TAPENTADOL IN THE FORM OF ITS BASE OR A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY THE HYDROCHLORIDE SALT.; REGISTERED: DE 75043 20100819; UK PL 21727/0032 - 0050 20110204